- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences
Analysts see longer recovery path to profitability for biotech firm
Apr. 3, 2026 at 11:08am
Got story updates? Submit your updates here. ›
Analysts' downgraded earnings forecasts for Kodiak Sciences suggest a longer road to profitability for the biotech firm.Palo Alto TodayKodiak Sciences Inc. (NASDAQ:KOD) - Stock analysts at Lifesci Capital decreased their Q1 2026 earnings estimates for Kodiak Sciences in a research report issued on Wednesday, April 1st. Lifesci Capital analyst P. Dolezal now anticipates the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.64). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share.
Why it matters
The downward revisions to Kodiak Sciences' near-term and multi-year earnings forecasts by Lifesci Capital and other analysts signal a longer recovery path to profitability for the biotech firm, raising risk for investors focused on short-term fundamentals.
The details
Lifesci Capital also issued estimates for Kodiak Sciences' Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.52) EPS. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Kodiak Sciences (NASDAQ:KOD) last released its earnings on March 31st, reporting a loss of ($1.04) per share, missing analysts' estimates of ($1.02).
- Lifesci Capital issued the revised estimates on April 1, 2026.
- Kodiak Sciences reported Q4 2025 earnings on March 31, 2026.
The players
Lifesci Capital
A stock research firm that covers Kodiak Sciences.
P. Dolezal
An analyst at Lifesci Capital who covers Kodiak Sciences.
Kodiak Sciences Inc.
A clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases.
What they’re saying
“Lifesci Capital analyst P. Dolezal now anticipates that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.64).”
— P. Dolezal, Analyst
The takeaway
The downward revisions to Kodiak Sciences' earnings forecasts by multiple analysts signal a longer recovery path to profitability for the biotech firm, raising risk for investors focused on near-term fundamentals.
